2-三氟甲基吡啶-5-硼酸频哪醇酯 | 1218790-39-6

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-三氟甲基吡啶-5-硼酸频哪醇酯
• 中文别名: 2-氟甲基吡啶-5-硼酸频哪醇酯
• 英文名称: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyridine
• CAS: 1218790-39-6
• 化学式: C₁₂H₁₅BF₃NO₂
• 分子量: 273.063
• InChiKey: SOMIPHAQTXODQM-UHFFFAOYSA-N

物化性质

• 沸点：
  298.8±40.0 °C(Predicted)
• 密度：
  1.18

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险类别：
  IRRITANT

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Trifluoromethylpyridine-5-boronic acid pinacol ester
Synonyms: 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyridine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Trifluoromethylpyridine-5-boronic acid pinacol ester
CAS number: 1218790-39-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H15BF3NO2
Molecular weight: 273.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-三氟甲基吡啶-5-硼酸频哪醇酯 在 copper diacetate 、 三乙胺 、 N-Boc-哌嗪 作用下， 以 乙腈 为溶剂， 反应 18.0h， 生成 2-三氟甲基吡啶
  参考文献：
  名称：

  铜电荷转移催化使（杂）芳基酸脱羧硼化和交叉偶联

  摘要：

  我们报告了一种用于芳基硼酸酯合成的铜催化策略，该策略利用光诱导配体到金属电荷转移 (LMCT) 将（杂）芳基酸转化为适合环境温度硼化的芳基自由基。这种近紫外过程在温和条件下发生，不需要对天然酸进行预功能化，并且广泛适用于各种芳基、杂芳基和药物底物。我们还报告了一种用于脱羧交叉偶联的一锅程序，该程序将催化 LMCT 硼酸化和钯催化的 Suzuki-Miyaura 芳基化、乙烯基化或与有机溴化物的烷基化结合起来，以获得一系列增值产品。通过开发异选择性双脱羧 C(sp 2 )–C(sp 2）偶联序列，铜催化的两种不同酸（包括药物底物）的 LMCT 硼化和卤化过程与随后的 Suzuki-Miyaura 交叉偶联配对。

  DOI：

  10.1021/jacs.2c01630
• 作为产物：
  描述：

  1-(6-(trifluoromethyl)pyridin-3-yl)butan-1-one 在 吡啶 、 2,6-二叔丁基-4-甲基苯酚 、 盐酸羟胺 、 sodium acetate 、 potassium carbonate 、 2-(4,5-二氢-4,4-二甲基-2-恶唑基)吡啶 、 四(3,5-二(三氟甲基)苯基)硼酸钠 、 三[3,4-双(三氟甲基)苯基]膦 、 palladium dichloride 作用下， 以 乙醇 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 12.0h， 生成 2-三氟甲基吡啶-5-硼酸频哪醇酯
  参考文献：
  名称：

  通过配体促进的CC键活化来转化芳基酮。

  摘要：

  芳族亲电试剂（芳基卤化物，芳基醚，芳基酸，芳基腈等）与亲核试剂的偶联是合成芳基化合物的核心方法。由于芳基酮的丰度，通过碳-碳键活化以类似方式进行芳基酮的转化可大大扩展合成芳基化合物的工具箱。这种方法的探索性研究通常基于环应变释放和螯合辅助引发的碳-碳裂解，并且产物也仅限于特定的结构基序。在这里，我们报告了一种配体促进β-碳消除的策略，以激活碳-碳键，这导致芳基酮发生一系列转化，从而生成有用的芳基硼酸酯，以及联芳基，芳基腈和芳基烯烃。吡啶-恶唑啉配体的使用对于这种催化转化至关重要。据报道，通过简单的一锅操作，芳基酮的克级硼酸酯化反应。该策略的潜在效用还通过丙磺舒，阿达帕林和脱氧雌酮，芬芳类香囊素和载脂蛋白的天然产物的晚期药物分子多样化而得到证明。

  DOI：

  10.1002/anie.202006740

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
  申请人：CALICO LIFE SCIENCES

  公开号：WO2017193063A1

  公开（公告）日：2017-11-09

  Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

  本文提供了用于调节综合应激反应（ISR）并治疗相关疾病、疾患和症状的化合物、组合物和方法。
• A Monophosphine Ligand Derived from Anthracene Photodimer: Synthetic Applications for Palladium-Catalyzed Coupling Reactions
  作者：Xin Wang、Wei-Gang Liu、Chen-Ho Tung、Li-Zhu Wu、Huan Cong

  DOI：10.1021/acs.orglett.9b02414

  日期：2019.10.18

  an air-stable dianthracenyl monophosphine ligand (diAnthPhos) which can be prepared in two steps from commercially available anthracene derivatives. The ligand exhibits excellent efficiency for palladium-catalyzed coupling reactions. In particular, Miyaura borylation of heterocycle-containing electrophiles can be facilitated employing the diAnthPhos ligand with a broad substrate scope and low catalyst

  在这里，我们提出了一种空气稳定的二蒽基单膦配体（diAnthPhos），它可以由市售的蒽衍生物分两步制备。该配体对于钯催化的偶联反应表现出优异的效率。特别地，使用具有宽底物范围和低催化剂负载的diAnthPhos配体可以促进含杂环亲电试剂的宫浦硼化。通过对含杂芳基的底物进行一锅Miyaura硼化/ Suzuki偶联方案，进一步证明了新配体的宝贵合成效用。
• [EN] SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020239999A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制NIK的化合物，以及包含这些化合物的药物组合物和使用方法。这些化合物和药物组合物预期能用于预防或治疗癌症（如包括白血病、淋巴瘤和多发性骨髓瘤的B细胞恶性肿瘤）、炎症性疾病、自身免疫疾病、免疫皮肤病学疾病（如掌跖脓疱病和化脓性汗腺炎）以及代谢紊乱疾病（如肥胖和糖尿病）。